Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2e) is the pathogen responsible
for the 2019 coronavirus disease pandemic (COVID-19), which has caused global health care
crises and overstretched health care resources, Scientific and clinical evidence is
evolving on the subacute and long-term effects of COVID-19, which can affect multiple
organ systems. As the population of patients recovering from COVID-19 grows, it is
critical to establish an understanding of the healthcare issues surrounding them.
COVID-19 is now recognized as a multi-organ disease with a broad spectrum of
manifestations.

Early reports suggest residual effects of SARS-CoV-2c infection, such as fatigue,
dyspnea, chest pain, cognitive impairment, arthralgia and impaired quality of life.
Cellular damage, a robust innate immune response with inflammatory cytokine production
and a procoagulant state induced by SARS-CoV-2 infection may contribute to these
sequelae. Survivors of previous coronavirus infections, including the 2003 SARS epidemic
and the 2012 Middle East Respiratory Syndrome (MERS) outbreak, have demonstrated a
similar set of persistent symptoms, reinforcing concerns about clinically significant
sequelae of COVID-19.

Some countries use several drugs to treat coronavirus. In one of its documents, the
Spanish Society of Medicine mentions the recommendations of the protocol developed for
the treatment of COVID-19. Specific antiviral treatment requires drugs such as
lopinavir/ritonavir administered orally. This drug is indicated to help control human
immunodeficiency virus (HIV) infection. It is only administered orally 0 in concomitant
treatment with interferon beta-lb. In this case Betaferon is recommended, which is
indicated for the treatment of multiple sclerosis. Interferons are proteins produced by
the body that help fight against attacks on the immune system, such as viral infections.
Lopinavir / ritonavir can also be used in combination with an alpha-2B interferon, such
as Intron A, which modifies the immune system response of the patient. the body's immune
system to help fight infections and serious illnesses.

Viusid (Catalysis Laboratories, Madrid, Spain) is a nutritional supplement with
recognized antioxidant and immunomodulatory properties that have beneficial effects on
clinical outcomes related to cirrhosis, such as survival, disease progression and the
development of hepatocellular carcinoma (HCC). It contains different molecules (ascorbic
acid, zinc and glycyrrhizic acid) with recognized antioxidant and immunomodulatory
properties. Glycyrrhizin (0.033g), the most important active ingredient of the
supplement, is known to have an immunomodulatory, antiviral and biological effect, and
has also demonstrated various anti-inflammatory properties (such as increased production
of IL-10: a potent anti-inflammatory cytokine that inhibits the synthesis of many
proinflammatory proteins), as well as an anti-apoptotic effect, hepatocyte proliferation
and stabilization of cell membranes in the liver. Recent data suggest that Viusid
ameliorates oxidative stress through the reduction of 105 lipid peroxidation products and
that it has an immunomodulatory effect on cytokine secretion through increased cytokine
secretion by the liver. cytokines through increased production of IFN-y and IL-l0,
decreased production of IL-ly, stabilized tumor necrosis factor and secretion in HCV
patients who have failed previous antiviral treatments.

Taking into account the benefits of Viusid, such as the reduction of inflammation and the
immunomodulatory effect, a randomized double-blind study is proposed to evaluate the
treatment with this food supplement in 200 patients with post-COVID syndrome diagnosed,
assessing the improvement of their symptoms before and after treatment for 1 month,
through clinical and paraclfnical examinations.